AMENDMENTS TO THE CLAIMS

Listing of Claims

1. (currently amended) A process for the preparation of a solid, orally administrable pharmaceutical composition comprising an active compound (I) that is 5-chloro-*N*-({5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide [[(I)]] in hydrophilized form, comprising the following steps:

   (a) first preparing granules comprising the active compound (I) in hydrophilized form by moist granulation

   (b) and converting the granules into the pharmaceutical composition, if appropriate with addition of pharmaceutically suitable additives.

2. (previously presented) The process according to Claim 1, wherein the moist granulation method used is fluidized bed granulation.

3. (previously presented) The process according to Claim 1, wherein the active compound (I) is employed in crystalline form.

4. (previously presented) The process according to Claim 3, wherein the active compound (I) is employed in micronized form.

5. (previously presented) The process according to Claim 1, wherein the active compound (I) suspended in the granulating liquid is introduced into the moist granulation.

6. (previously presented) The process according to Claim 1, wherein the resulting pharmaceutical composition is a tablet rapidly releasing the active compound (I).

7. (previously presented) A solid, orally administrable pharmaceutical composition prepared by the process according to Claim 1.

8. (currently amended) A solid, orally administrable pharmaceutical composition, comprising ~~active compound~~ an active compound (I) that is 5-chloro-*N*-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]- 1,3-oxazolidin-5-yl}-methyl)-2-thiophene-carboxaniide [[(I)]] in hydrophilized form.

9. (previously presented) The pharmaceutical composition according to Claim 8, comprising the active compound (I) in crystalline form.

10. (previously presented) The phannaceutical composition according to Claim 9, comprising the active compound (I) in micronized form.

11. (currently amended) The pharmaceutical composition according to Claim 7, wherein the active compound (I) is present in a concentration of 1 to 60% based on the total mass of the ~~formulation~~ composition.

12. (previously presented) The pharmaceutical composition according to Claim 7, further comprising sodium lauryl sulphate as a wetting agent.

13. (previously presented) The pharmaceutical composition according to Claim 12, wherein said sodium lauryl sulphate is present in a concentration of 0.1 to 5%, based on the total mass.

14. (previously presented) The pharmaceutical composition according to Claim 7, further comprising hydroxypropylmethylcellulose as a hydrophilic binding agent.

15. (currently amended) The pharmaceutical composition according to Claim 14, wherein said hydroxypropylmethylcellulose is present in a concentration of 1 to 15%, based on the total mass.

16. (currently amended) The pharmaceutical composition according to Claim 7 that is in the form of a tablet.

17. (currently amended) The pharmaceutical composition according to Claim 16 that is in the form of a rapid-release tablet.

18. (previously presented) The pharmaceutical composition according to Claim 16, characterized in that the tablet is covered with a coating.

19. (currently amended) A method for the prophylaxis and/or treatment of thromboembolic diseases comprising administering an effective amount of the pharmaceutical composition of ~~claim~~ Claim 7.

20. (currently amended) A method for the prophylaxis and/or treatment of thromboemblic diseases comprising administering an effective amount of 5-chloro-*N*-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide [[(I)]] in hydrophilized form.

21. (Cancelled)